Biblio
] , “Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42.”, J Alzheimers Dis, vol. 99, no. 3, pp. 877-881, 2024.
, “The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes.”, J Alzheimers Dis, vol. 94, no. 2, pp. 497-507, 2023.
, “Copper Imbalance in Alzheimer's Disease and Its Link with the Amyloid Hypothesis: Towards a Combined Clinical, Chemical, and Genetic Etiology.”, J Alzheimers Dis, vol. 83, no. 1, pp. 23-41, 2021.
